G42 and Mubadala Introduce M42 to advanced AI-driven and precision healthcare globally

In July 2026, G42 and Mubadala officially launched M42, a new healthcare organization created by combining the skills of Mubadala Health and G42 Healthcare. To provide integrated patient-centered healthcare services, the recently established corporation plans to mix cutting-edge technology like artificial intelligence, genomics, and data analytics with a vast network of medical facilities. M42 hopes to boost healthcare delivery both domestically in the United Arab Emirates and abroad, improve clinical results, and expedite precision medicine innovation through this strategic partnership.

The creation of M42 is a reflection of how digital technologies are becoming more and more important in modern healthcare. Globally, healthcare systems are moving toward data-driven, tailored care models that prioritize early diagnosis, personalized treatment, and illness prevention. M42 aims to provide a healthcare ecosystem that enhances patient care and facilitates more effective and knowledgeable medical decision-making by fusing technological innovation with clinical competence. The business will use AI and sophisticated analytics to assist medical professionals in early disease diagnosis, treatment strategy optimization, and overall healthcare efficiency.

M42 combines Mubadala Health's network of hospitals, specialty clinics, labs, and medical facilities with G42 Healthcare's proficiency in genomics, artificial intelligence, and digital health. This unified structure enables the firm to deliver comprehensive healthcare services spanning prevention, diagnosis, treatment, rehabilitation, and long-term disease management. The integrated strategy is expected to promote collaboration among healthcare professionals while ensuring patients receive more coordinated and individualized care throughout their healthcare journey.

The development of precision medicine is one of the new organizations' main priorities. M42 seeks to provide individualized treatment recommendations based on each patient's distinct genetic profile and medical history by fusing genomic sequencing with artificial intelligence and extensive clinical data analysis. With this method, medical professionals can detect illnesses earlier, provide more focused treatments, and enhance treatment efficacy while cutting down on pointless medical procedures. According to the business, precision medicine will be crucial to preventive and predictive healthcare in the future.

A key component of M42 healthcare operations will be artificial intelligence. The business intends to use AI in clinical decision support and diagnostic imaging. Laboratory services, disease prediction, hospital operations, and population health management. Clinicians will be able to diagnose patients more quickly, make better clinical decisions, and improve patient outcomes with the use of AI-powered systems that handle massive amounts of healthcare data more effectively. By automating standard administrative and clinical operations, these technologies are also anticipated to increase operational efficiency.

Through strategic partnerships with healthcare providers, pharmaceutical businesses, biotechnology firms, academic institutions, and research organizations, M42 hopes to increase its global footprint in addition to bolstering healthcare services in the United Arab Emirates. The organization hopes to assist healthcare innovation, expedite medical research, and encourage the use of cutting-edge technologies throughout the world's healthcare systems by forming worldwide alliances. It is anticipated that these partnerships would enhance access to high-quality healthcare services and aid in the creation of next-generation healthcare solutions.

Hospitals, specialist clinics, diagnostic labs, genetic research facilities, and digital health platforms are all part of the vast healthcare network that M42 oversees. The organizations can provide a variety of specialized healthcare services while promoting clinical research innovation and medical education thanks to this integrated infrastructure. M42 aims to construct a linked healthcare ecosystem that can meet the changing demands of patients and healthcare professionals by fusing cutting-edge technology with well-established medical facilities.

According to the company, M42 was founded with the goal of revolutionizing healthcare by innovation, teamwork, and cutting-edge technologies. The group hopes to improve patient outcomes. Increase healthcare accessibility and promote more sustainable healthcare systems by incorporating artificial intelligence, precision medicine, and digital healthcare solutions into standard clinical practice. The launch also supports the UAE's goal to lead the world in life sciences and healthcare innovation.

The launch of M42 demonstrates the increasing significance of integrated healthcare platforms that blend clinical knowledge and digital technologies. Businesses like M42 are anticipated to have a big impact on how healthcare is shaped in the future if healthcare institutions continue to engage in AI, genomics, and personalized medicine. The organization's technology-driven strategy seeks to provide more proactive, effective, and patient-focused healthcare while advancing clinical care and medical research worldwide.

Impact on the Healthcare Industry

According to Precedence Research, the use of digital healthcare technologies, genetic precision medicines, and artificial intelligence is rapidly changing the healthcare sector. To improve clinical decision-making, improve patient outcomes, and enable individualized treatment options, healthcare providers are investing more and more in integrated healthcare ecosystems. By fusing decision-making, healthcare solution outcomes, and clinical networks to provide increased options, connected, and data-driven healthcare services, M42's debut follows this trend. Ecosystems anticipated to integrate AI-driven cutting-edge technologies with hospital networks, labs, and research facilities will boost data-centric care services. oM42's wide increase in operational effectiveness and spur in health care innovation.

Impact on the Digital Health Market

The global digital health market size is calculated at USD 420.08 billion in 2025 and is predicted to increase from USD 483.07 billion in 2026 to approximately USD 1,171.24 billion by 2035, expanding at a CAGR of 10.8% from 2026 to 2035.

According to Precedence Research, with the growing use of telemedicine, cutting-edge electronic health records, hospitals' patient monitoring, artificial intelligence, and patient-centric healthcare platforms worldwide, the digital health market is significantly more effective. To increase the efficiency and accessibility of healthcare, governments and healthcare institutions are aggressively funding digital transformation projects. By combining AI digital health platforms and sophisticated data analytics into a single healthcare ecosystem, the introduction of M42 supports this market trend. It is anticipated that the company's emphasis on technology-enabled healthcare delivery will promote increased acceptance of digital health solutions and aid in the modernization of healthcare and the global digital health industry.

Impact on the Precision Medicine Market

The global precision medicine market size is estimated to be USD 119.03 billion in 2025 and is predicted to increase. It's from USD 138.67 billion in 2026 to approximately technology-enabled expansion by 2035, with a CAGR of 16.26% from 2026 to 2035. 

As health solutions and professionals increasingly use genomes, molecular diagnostics, and personalized medicines to enhance treatment outcomes, the worldwide precision medicine market is growing quickly. Precedence Research claims that the market is expanding due to rising investments in genomic research, improvements in sequencing technologies, and the growing need for customized treatment plans. M42 focuses on genomics, AI-powered analytics, and personalized healthcare, helping to sustain the research of precision medicine technologies. The company anticipates accelerating the adoption of precision medicine and promoting more efficient patient-specific healthcare solutions by utilizing genetic insights and sophisticated data analysis to customize therapies for M42's individual patients.

About M42

With analytics quarters located in Abu Dhabi, United Arab Emirates, M42 is a multinational health technology firm. The company, which was founded as a result of the merger of G42 Healthcare and Mubadala Health, offers comprehensive healthcare solutions integrating genomics, digital health, artificial intelligence, and clinical care. M42 uses Healthcare Edge tech, patient-specific genomics, prevention, health, diagnosis, treatment, intelligence, and population health management while running a vast network of hospitals, specialty clinics, labs, and research facilities. By enabling precision medicine, bolstering digital healthcare infrastructure, and increasing access to high-quality patient care across cutting-edge markets, the company hopes to accelerate diagnosis, treatment, and the healthcare industry.